Neuroprotection by Mucuna Pruriens in Neurodegenerative Diseases

Overview

Journal Neurochem Res

Specialties Chemistry
Neurology

Date 2022 Apr 5

PMID 35380400

Authors

Walia Zahra

Hareram Birla

Saumitra Sen Singh

Aaina Singh Rathore

Hagera Dilnashin

Richa Singh

Priyanka Kumari Keshri

Priyanka Gautam

Surya Pratap Singh

Affiliations

Soon will be listed here.

Abstract

The medicinal plant Mucuna pruriens (Fabaceae) is widely known for its anti-oxidative and anti-inflammatory properties. It is a well-established drug in Ayurveda and has been widely used for the treatment of neurological disorders and male infertility for ages. The seeds of the plant have potent medicinal value and its extract has been tested in different models of neurodegenerative diseases, especially Parkinson's disease (PD). Apart from PD, Mucuna pruriens is now being studied in models of other nervous systems disorders such as Alzheimer's disease (AD), Amyotrophic lateral sclerosis (ALS) and stroke because of its neuroprotective importance. This review briefly discusses the pathogenesis of PD, AD, ALS and stroke. It aims to summarize the medicinal importance of Mucuna pruriens in treatment of these diseases, and put forward the potential targets where Mucuna pruriens can act for therapeutic interventions. In this review, the effect of Mucuna pruriens on ameliorating the neurodegeneration evident in PD, AD, ALS and stroke is briefly discussed. The potential targets for neuroprotection by the plant are delineated, which can be studied further to validate the hypothesis regarding the use of Mucuna pruriens for the treatment of these diseases.

Citing Articles

Effect of seed extract on depression-like behavior derived from mild traumatic brain injury in rats.

Mata-Bermudez A, Trejo-Chavez R, Martinez-Vargas M, Perez-Arredondo A, de Los Angeles Martinez-Cardenas M, Diaz-Ruiz A Biomedicine (Taipei). 2024; 14(3):23-30.

PMID: 39386181 PMC: 11460573. DOI: 10.37796/2211-8039.1461.

Invertebrate genetic models of amyotrophic lateral sclerosis.

Zhou L, Xu R Front Mol Neurosci. 2024; 17:1328578.

PMID: 38500677 PMC: 10944931. DOI: 10.3389/fnmol.2024.1328578.

Nanophytomedicines as Therapeutic Agents for Parkinson's Disease.

Burns J, Buck A, D Souza S, Dube A, Bardien S ACS Omega. 2023; 8(45):42045-42061.

PMID: 38024675 PMC: 10652730. DOI: 10.1021/acsomega.3c04862.

The neuroprotective effect of quercetin nanoparticles in the therapy of neuronal damage stimulated by acrolein.

Sanad S, Farouk R, Nassar S, Alshahrani M, Suliman M, Ahmed A Saudi J Biol Sci. 2023; 30(11):103792.

PMID: 37711970 PMC: 10498005. DOI: 10.1016/j.sjbs.2023.103792.

What Are the Key Gut Microbiota Involved in Neurological Diseases? A Systematic Review.

Bonnechere B, Amin N, van Duijn C Int J Mol Sci. 2022; 23(22).

PMID: 36430144 PMC: 9696257. DOI: 10.3390/ijms232213665.

References

Suresh S, Prithiviraj E, Lakshmi N, Ganesh M, Ganesh L, Prakash S . Effect of Mucuna pruriens (Linn.) on mitochondrial dysfunction and DNA damage in epididymal sperm of streptozotocin induced diabetic rat. J Ethnopharmacol. 2012; 145(1):32-41. DOI: 10.1016/j.jep.2012.10.030. View

Yadav S, Prakash J, Chouhan S, Singh S . Mucuna pruriens seed extract reduces oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in paraquat-induced Parkinsonian mouse model. Neurochem Int. 2013; 62(8):1039-47. DOI: 10.1016/j.neuint.2013.03.015. View

Dhanasekaran M, Tharakan B, Manyam B . Antiparkinson drug--Mucuna pruriens shows antioxidant and metal chelating activity. Phytother Res. 2007; 22(1):6-11. DOI: 10.1002/ptr.2109. View

Diamond S, Markham C, HOEHN M, McDowell F, Muenter M . Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol. 1987; 22(1):8-12. DOI: 10.1002/ana.410220105. View

McNaught K, Olanow C, Halliwell B, Isacson O, Jenner P . Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci. 2001; 2(8):589-94. DOI: 10.1038/35086067. View

Rao R, Bredesen D . Misfolded proteins, endoplasmic reticulum stress and neurodegeneration. Curr Opin Cell Biol. 2004; 16(6):653-62. PMC: 3970707. DOI: 10.1016/j.ceb.2004.09.012. View

Block M, Zecca L, Hong J . Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2006; 8(1):57-69. DOI: 10.1038/nrn2038. View

Suzumura A, Takeuchi H, Zhang G, Kuno R, Mizuno T . Roles of glia-derived cytokines on neuronal degeneration and regeneration. Ann N Y Acad Sci. 2006; 1088:219-29. DOI: 10.1196/annals.1366.012. View

Shahidi F . Antioxidants in food and food antioxidants. Nahrung. 2000; 44(3):158-63. DOI: 10.1002/1521-3803(20000501)44:3<158::AID-FOOD158>3.0.CO;2-L. View

10.

Levites Y, Weinreb O, Maor G, Youdim M, Mandel S . Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem. 2001; 78(5):1073-82. DOI: 10.1046/j.1471-4159.2001.00490.x. View

11.

Carvalho M, Barca F, Agnez-Lima L, Batistuzzo de Medeiros S . Evaluation of mutagenic activity in an extract of pepper tree stem bark (Schinus terebinthifolius Raddi). Environ Mol Mutagen. 2003; 42(3):185-91. DOI: 10.1002/em.10183. View

12.

Ferreira-Machado S, Rodrigues M, Nunes A, Dantas F, De Mattos J, Silva C . Genotoxic potentiality of aqueous extract prepared from Chrysobalanus icaco L. leaves. Toxicol Lett. 2004; 151(3):481-7. DOI: 10.1016/j.toxlet.2004.03.014. View

13.

Manyam B, Dhanasekaran M, Hare T . Effect of antiparkinson drug HP-200 (Mucuna pruriens) on the central monoaminergic neurotransmitters. Phytother Res. 2004; 18(2):97-101. DOI: 10.1002/ptr.1407. View

14.

Luk K, Kehm V, Carroll J, Zhang B, OBrien P, Trojanowski J . Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012; 338(6109):949-53. PMC: 3552321. DOI: 10.1126/science.1227157. View

15.

Amer D, Irvine G, El-Agnaf O . Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders. Exp Brain Res. 2006; 173(2):223-33. DOI: 10.1007/s00221-006-0539-y. View

16.

Ehrnhoefer D, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R . EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol. 2008; 15(6):558-66. DOI: 10.1038/nsmb.1437. View

17.

Bieschke J, Russ J, Friedrich R, Ehrnhoefer D, Wobst H, Neugebauer K . EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci U S A. 2010; 107(17):7710-5. PMC: 2867908. DOI: 10.1073/pnas.0910723107. View

18.

Zhu M, Rajamani S, Kaylor J, Han S, Zhou F, Fink A . The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J Biol Chem. 2004; 279(26):26846-57. DOI: 10.1074/jbc.M403129200. View

19.

Rao J, Dua V, Ulmer T . Characterization of alpha-synuclein interactions with selected aggregation-inhibiting small molecules. Biochemistry. 2008; 47(16):4651-6. DOI: 10.1021/bi8002378. View

20.

Ono K, Yamada M . Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem. 2006; 97(1):105-15. DOI: 10.1111/j.1471-4159.2006.03707.x. View